MLN Matters® Number: MM8162
Related Change Request (CR) #: CR 8162
Related CR Release Date: January 25, 2013
Effective Date: January 1, 2013
Related CR Transmittal #: R2639CP
Implementation Date: April 1, 2013

Healthcare Common Procedure Coding System (HCPCS) Codes Subject to and Excluded from Clinical Laboratory Improvement Amendments (CLIA) Edits

Provider Types Affected

This MLN Matters® Article is intended for clinical diagnostic laboratories submitting claims to Medicare contractors (carriers and A/B Medicare Administrative Contractors (MACs)) for services to Medicare beneficiaries.

Provider Action Needed

This article is based on Change Request (CR) 8162, which informs Medicare contractors about the new Healthcare Common Procedure Coding System (HCPCS) codes for 2013 that are both subject to and excluded from Clinical Laboratory Improvement Amendments (CLIA) edits. The CR also lists the HCPCS codes discontinued as of December 31, 2012.

Make sure that your billing staffs are aware of these CLIA-related changes for 2013 and that you remain current with CLIA certification requirements.

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2011 American Medical Association.
Background

The CLIA regulations require a facility to be appropriately certified for each test performed. To ensure that the Medicare and Medicaid Programs only pay for laboratory tests performed in certified facilities, each claim for a HCPCS code that is considered a CLIA laboratory test is currently edited at the CLIA certificate level.

The HCPCS codes that are considered a laboratory test under CLIA change each year. Contractors need to be informed about the new HCPCS codes that are both subject to CLIA edits and excluded from CLIA edits.

Discontinued Codes

The following HCPCS codes were discontinued on December 31, 2012:

<table>
<thead>
<tr>
<th>HCPCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>83890</td>
<td>Molecular diagnostics; molecular isolation or extraction, each nucleic acid type (i.e., DNA or RNA)</td>
</tr>
<tr>
<td>83891</td>
<td>Molecular diagnostics; isolation or extraction of highly purified nucleic acid, each nucleic acid type (i.e., DNA or RNA)</td>
</tr>
<tr>
<td>83892</td>
<td>Molecular diagnostics; enzymatic digestion, each enzyme treatment</td>
</tr>
<tr>
<td>83893</td>
<td>Molecular diagnostics; dot/slot blot production, each nucleic acid preparation,</td>
</tr>
<tr>
<td>83894</td>
<td>Molecular diagnostics; separation by gel electrophoresis (e.g., agarose, polyacrylamide), each nucleic acid preparation</td>
</tr>
<tr>
<td>83896</td>
<td>Molecular diagnostics; nucleic acid probe, each</td>
</tr>
<tr>
<td>83897</td>
<td>Molecular diagnostics; nucleic acid transfer (e.g., southern, northern), each nucleic acid preparation</td>
</tr>
<tr>
<td>83898</td>
<td>Molecular diagnostics; amplification, target, each nucleic acid sequence</td>
</tr>
<tr>
<td>83900</td>
<td>Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences</td>
</tr>
<tr>
<td>83901</td>
<td>Molecular diagnostics; amplification, target, multiplex, each additional nucleic acid sequence beyond 2 (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>83902</td>
<td>Molecular diagnostics; reverse transcription</td>
</tr>
<tr>
<td>83903</td>
<td>Molecular diagnostics; mutation scanning, by physical properties (e.g., single strand conformational polymorphisms [sscp], heteroduplex, denaturing gradient gel electrophoresis [DGGE], RNA’ASE a), single segment, each</td>
</tr>
<tr>
<td>83904</td>
<td>Molecular diagnostics; mutation identification by sequencing, single segment, each segment</td>
</tr>
<tr>
<td>83905</td>
<td>Molecular diagnostics; mutation identification by allele specific transcription, single segment, each segment</td>
</tr>
<tr>
<td>83906</td>
<td>Molecular diagnostics; mutation identification by allele specific translation, single segment, each segment</td>
</tr>
<tr>
<td>83907</td>
<td>Molecular diagnostics; lysis of cells prior to nucleic acid extraction (e.g., stool specimens, paraffin embedded tissue), each specimen</td>
</tr>
</tbody>
</table>
### New Codes for 2013

In 2012, there were 101 new HCPCS codes for molecular pathology (i.e., 81200 through 81408) that were subject to the CLIA regulations, were not payable by Medicare and were not included in the recurring update notification for 2012 (i.e., Change Request 7778). For 2013, these 101 molecular HCPCS codes have been placed on the Medicare Clinical Laboratory Fee Schedule. The 101 are included in the attachment to CR8162.

The HCPCS codes listed below are new for 2013 and are subject to CLIA edits. The list does not include new HCPCS codes for waived tests or provider-performed procedures. The HCPCS codes listed below require a facility to have either a CLIA certificate of registration (certificate type code 9), a CLIA certificate of compliance (certificate type code 1), or a CLIA certificate of accreditation (certificate type code 3). A facility without a valid, current, CLIA certificate, with a current CLIA certificate of waiver (certificate type code 2) or with a current CLIA certificate for provider-performed microscopy procedures (certificate type code 4) must not be permitted to be paid for these tests.

The new HCPCS codes for 2013 are the following:

- **81201** - APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence,
- **81202** - APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants,
• 81203 - APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants,
• 81235 - EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 Irea deletion, L858R, T790M, G719A, G719S, L861Q),
• 81252 - GJB2 (gap junction protein, beta 2, 26kDa; Connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence,
• 81253 - GJB2 (gap junction protein, beta 2, 26kDa; known familial variants,
• 81254 - GJB6 (gap junction protein, beta 6, 30 kDa, Connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309KB [DEL(GJB6-D13S1830)] and 232KB [DEL(GJB6-D13S1854)]),
• 81321 - PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis,
• 81322 - PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant,
• 81323 - PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant,
• 81324 - PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis,
• 81325 - PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence analysis,
• 81326 - PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant,
• 81479 - Unlisted molecular pathology procedure,
• 82777 - Galectin-3,
• 86152 - Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood),
• 86153 - Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood); physician interpretation and report, when required,
• 86711 - JC (John Cunningham) virus,
• 86828 - Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads; ELISA, flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I and Class II HLA antigens,
• 86829 - Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I or Class II HLA antigens,
• 86830 - Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); antibody identification by qualitative panel using complete HLA phenotypes, HLA Class I,
• 86831 - Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); antibody identification by qualitative panel using complete HLA phenotypes, HLA Class II,
• 86832 - Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); high definition qualitative panel for identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class I,
• 86833 - Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); high definition qualitative panel for identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class II,
• 86834 - Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); semi-quantitative panel (eg, titer), HLA Class I,
• 86835 - Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); semi-quantitative panel (eg, titer), HLA Class II,
• 87631 - Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 3-5 targets,
• 87632 - Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 6-11 targets,
• 87633 - Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 12-25 targets,
• 87910 - Infectious agent genotype analysis by nucleic acid (DNA or RNA); cytomegalovirus,
• 87912 - Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis B virus, and
• 88375 - Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session.

Additionally, there were 9 new HCPCS codes for multi-analyte assays with algorithmic analyses (i.e., 81500 through 81512, and 81599) in 2013. The testing described by these codes is subject to the CLIA regulations, however, they are not payable by Medicare for CY 2013. Hence, these 9 codes were not included in CR8162.

**Additional Information**


If you have any questions, please contact your carrier or A/B MAC at their toll-free number, which may be found at [http://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/provider-compliance-interactive-map/index.html](http://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/provider-compliance-interactive-map/index.html) on the CMS website.

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.

CPT only copyright 2011 American Medical Association.